{"nctId":"NCT00633919","briefTitle":"Efficacy of SLITone in House Dust Mite Allergic Patients","startDateStruct":{"date":"2006-07"},"conditions":["Allergy"],"count":124,"armGroups":[{"label":"Active","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: SLITone(TM) Dermatophagoides mix","Drug: Salbutamol inhaler","Drug: Budesonide/formoterol inhaler","Drug: Prednisone tablet","Drug: Desloratadine tablet","Drug: Budesonide nasal spray"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo","Drug: Salbutamol inhaler","Drug: Budesonide/formoterol inhaler","Drug: Prednisone tablet","Drug: Desloratadine tablet","Drug: Budesonide nasal spray"]}],"interventions":[{"name":"SLITone(TM) Dermatophagoides mix","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Salbutamol inhaler","otherNames":["Ventilastin"]},{"name":"Budesonide/formoterol inhaler","otherNames":["Symbicort"]},{"name":"Prednisone tablet","otherNames":[]},{"name":"Desloratadine tablet","otherNames":["Aerus"]},{"name":"Budesonide nasal spray","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A clinical history of house dust mite induced persistent mild to moderate. asthma, with or without concurrent rhinoconjunctivitis, of at least 1 year of evolution.\n* Demonstration of a positive specific serum IgE test to Dermatophagoides during the year prior to the screening visit (CAP Class 2 or higher or equivalent).\n* Positive Skin Prick Test response (wheal diameter ≥ 3 mm) to Dermatophagoides mix.\n* If pre-menopausal female of childbearing potential, the subject must test negative on standard urine pregnancy test.\n* Willingness to comply with this protocol.\n\nExclusion Criteria:\n\n* FEV1 \\< 70% of predicted value with appropriate medication.\n* Asthma controlled at randomization without need of inhaled corticosteroids or with a dose higher than 1000 µg/day of beclometasone or equivalent.\n* A clinical history of symptomatic perennial allergic asthma caused by allergens to which the subjects is regularly exposed (Alternaria, cat), other than house dust mites.\n* Chronic sinusitis.\n* Aspirin or sulfite intolerance.\n* Chronic obstructive pulmonary disease.\n* Current severe atopic dermatitis.\n* Severe asthma.\n* Use of an investigational drug within 30 days prior to screening.\n* Previous immunotherapy with house dust mite allergens for at least 2 years within the previous 10 years.\n* At randomisation, current symptoms of, or treatment for, upper respiratory tract infection, acute sinusitis, acute otitis media or other relevant infectious process (se-rous otitis media is not an exclusion criterion).\n* Physical examination with clinically relevant findings.\n* Any of the following underlying conditions known or suspected to be present: Cystic fibrosis, malignancy, insulin-dependent diabetes, malabsorption or malnutrition, renal or hepatic insufficiency, chronic infection, drug dependency or alco-holism, ischaemic heart disease or angina requiring current daily medication or with any evidence of disease making implementation of the protocol or interpretation of the protocol results difficult or jeopardising the safety of the subject (e.g. clinically significant cardiovascular, serious immunopathologic, immunodeficiency whether acquired or not, hepatic, neurologic, psychiatric, endocrine, or other ma-jor systemic disease).\n* Immunosuppressive treatment.\n* A mental condition rendering the subject unable to understand the nature, scope and possible consequences of the trial, and/or evidence of an uncooperative attitude.\n* Unlikely to be able to complete the trial.\n* Unwillingness to comply with trial protocol regimen for asthma and/or rhinoconjunctivitis medication.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Average Daily Asthma Medication Score During a 2-months Evaluation Period in Autumn 2008","description":"Scoring per inhalation/tablet: 1-2 inhalations twice daily of salbutamol (200 ug per inhalation), 2 scores; 1-2 inhalation twice daily of budesonide/formoterol 80 (4.5 ug per inhalation), 4 scores; 1 inhalation twice daily of budesonide/formoterol 160 (4.5 ug per inhalation), 8 scores; up to 10 tablets once daily of prednisone (5 mg), 1.6 scores. The total maximum daily scores were 40.\n\nThe daily score for each medication step was calculated by multiplying the score per inhalation/tablet with the number of inhalations/tablets used (entered as units in the daily diary by the subject).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"5.9"},{"groupId":"OG001","value":"4.7","spread":"5.4"}]}]}]},{"type":"SECONDARY","title":"Average Daily Asthma Medication Score During a 2-months Evaluation Period in Autumn 2007","description":"Scoring per inhalation/tablet: 1-2 inhalations twice daily of salbutamol (200 ug per inhalation), 2 scores; 1-2 inhalation twice daily of budesonide/formoterol 80 (4.5 ug per inhalation), 4 scores; 1 inhalation twice daily of budesonide/formoterol 160 (4.5 ug per inhalation), 8 scores; up to 10 tablets once daily of prednisone (5 mg), 1.6 scores. The total maximum daily scores were 40.\n\nThe daily score for each medication step was calculated by multiplying the score per inhalation/tablet with the number of inhalations/tablets used (entered as units in the daily diary by the subject).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"5.1"},{"groupId":"OG001","value":"3.6","spread":"3.9"}]}]}]},{"type":"SECONDARY","title":"Global Evaluation of Efficacy by Subject at the End of The Evaluation Period in 2008","description":"The treatment efficacy was rated by subjects at the end of the evaluation period in autumn 2008. Subjects rated their asthma symptoms in comparison to previous autumn using the categories: \"much worse\", \"worse\", \"the same\", \"better\", or \"much better\".\n\nThe categories \"much better\" or \"better\" were grouped as \"improved\". The categories \"the same\", \"worse\" or \"much worse\" were grouped as \"not improved\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Global Evaluation of Efficacy by Investigator at the End of the Evaluation Period in Autumn 2008","description":"The treatment efficacy was rated by investigators at the end of the evaluation period in autumn 2008. Investigators rated the asthma symptoms in comparison to when subjects entered the trial, using the categories: \"much worse\", \"worse\", \"the same\", \"better\", or \"much better\".\n\nThe categories \"much better\" or \"better\" were grouped as \"improved\". The categories \"the same\", \"worse\" or \"much worse\" were grouped as \"not improved\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Global Evaluation of Efficacy by Subject and Investigator at the End of the Evaluation Period in Autumn 2007","description":"The treatment efficacy was rated by both subject and investigator at the end of the evaluation period in autumn 2007. Subjects rated their asthma symptoms in comparison to previous autumns and investigators rated the asthma symptoms in comparison to when subjects entered the trial, using the categories: \"much worse\", \"worse\", \"the same\", \"better\", or \"much better\".\n\nThe categories \"much better\" or \"better\" were grouped as \"improved\". The categories \"the same\", \"worse\" or \"much worse\" were grouped as \"not improved\".","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":63},"commonTop":["Nasopharyngitis","Influenza","Bronchitis","Upper respiratory tract infection","Hypertension"]}}}